• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300871.SZ
Share

Wuhan Hvsen Biotechnology Co.,Ltd. Stocks

CN¥ 21.02Last Updated 11.09.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

CN¥ 696.67M

CN¥ 21.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

11.09.2026 13:11

Diesel prices in the U.S. have exceeded $6 per gallon for the first time in history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026